Welltower

WELL · NYSE

$238.08+$4.57 (+1.96%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $233.51

WELL analyst rating

BuyConsensus of 18 analysts over the last 12 months. 83% rate it a buy.

Strong buy0
Buy15
Hold3
Underperform0
Sell0

12-month price target · 24 analysts

Average $268.57 (+12.8% upside)

Low: $235.33
Now: $238.08
High: $306.60

Upgrades and downgrades

The latest rating actions, newest first

WELL analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 19, 2026	Maintains	Overweight	$266.00 → $268.00	48%
Barclays	Oct 13, 2026	Maintains	Equal-Weight	$259.00 → $246.00	38%
JP Morgan	Sep 24, 2026	Upgrade	Neutral → Overweight	$260.00	53%
Evercore ISI Group	Sep 21, 2026	Maintains	Outperform	$260.00 → $256.00	45%
Jefferies	Sep 15, 2026	Initiates	Buy	$261.00 → $275.00	33%
Scotiabank	Sep 2, 2026	Maintains	Sector Outperform	$244.00 → $251.00	47%
Morgan Stanley	Sep 1, 2026	Maintains	Overweight	$215.00 → $251.00	56%
Wells Fargo	Sep 1, 2026	Maintains	Overweight	$237.00 → $266.00	51%
Barclays	Aug 31, 2026	Maintains	Equal-Weight	$254.00 → $259.00	38%
Keybanc	Aug 4, 2026	Maintains	Overweight	$240.00 → $275.00	63%

The case for and against

Updated Oct 15, 2026

Bull case

Welltower is well positioned to outperform because its diversified healthcare portfolio of 2,950 properties across senior housing, medical office, and skilled nursing/postacute care pairs scale with strong fundamentals in a fragmented market. Its Canadian clinic platform, led by ~275 outpatient clinics and supported by double-digit growth, margin expansion, and a robust M&A pipeline, should keep driving accretive revenue while U.S. asset monetizations simplify the story, reduce leverage, and fund additional buybacks and expansion. With WELLSTAR’s Rule of 40+ performance, AI-enabled efficiency gains, and the planned focus on Canada, investors should increasingly value its durable organic growth and capital-efficient consolidation strategy.

Bear case

Welltower is viewed negatively because its growth thesis depends heavily on active M&A, yet slower clinic deal activity, higher acquisition valuations, and integration failures could prevent the company from backfilling CRH’s contribution to Adj. EBITDA and FCF. The company also faces meaningful regulatory, reimbursement, and capital-market risk, while a tightened financing environment could limit near-term investment activity and leave margins flat or declining despite its 0.9x EV/Revenue and 8.0x EV/EBITDA trading multiples versus higher peer levels. In addition, the stock appears to already discount significant growth, so any moderation in SHOP recovery, underwriting missteps, or lack of monetization from U.S. assets could compress valuation further.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.